Hyderabad-based pharmaceutical company Aurobindo Pharma limited (APL) on Wednesday stated that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Lamivudine and Zidovudine tablets.
According to APL, the tablets, which are ready for launch, are the generic equivalent of ViiV Healthcare Company's Combivir tablets and are indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected persons. The annual sale of the product is approximately $265 million.
APL currently has a total of 150 abbreviated new drug applications approved by the USFDA.
The company's scrip was currently trading at Rs 104 on BSE, down 2.12% over the previous day's close of Rs 106.25.
